Safety assessment, radioiodination and preclinical evaluation of antinuclear antibody as novel medication for prostate cancer in mouse xenograft model

This study aims to provide in vitro and in vivo data to support the utilization of antinuclear antibodies (ANAs) as novel tools for the diagnosis and treatment of prostate cancers. The hematological, biochemical, and histological toxicities of ANAs were assessed at the doses of 5 and 50 μg per mouse. Radiolabeling study was then conducted with ANA and 131I using the chloramine T method, and the biodistribution and treatment efficacy were subsequently investigated in a PC3 xenograft model. No changes in clinical behavior or signs of intoxication, necrosis, or malignancy were observed in ANA-treated mice. 131I-ANA was obtained in very high yield and radiochemical purity, at 94.97 ± 0.98% and 98.56 ± 0.29%, respectively. They achieved immunoreactivity fraction of 0.841 ± 0.17% with PC-3 cells. Levels of radiolabeled ANAs were 1.15-10.14 times higher in tumor tissues than in other examined organs at 24 h post-injection. The tumor growth inhibition rates were 28.33 ± 5.01% in PC3 xenografts mice treated with 131I-ANAs compared with controls and a nearly twofold improvement in median survival was observed. These results demonstrate that radioimmunotherapy of radiolabeled natural ANAs may be an effective treatment for prostate tumors.

Preparation, biological evaluation and radiolabeling of [99mTc]-technetium tricarbonyl procainamide as a tracer for heart imaging in mice

This study focuses on the synthesis and preliminary bio-evaluation of [99mTc]-technetium tricarbonyl procainamide ([99mTc]-technetium tricarbony PA) as a viable cardiac imaging agent. The compound, [99mTc]-technetium tricarbony PA, was synthesized by labelling procainamide with a [99mTc]-technetium tricarbonyl core, yielding a high radiochemical yield and radiochemical purity of 98%. Under optimal circumstances, high radiochemical yield and purity were obtained utilizing [99mTc]-technetium tricarbonyl core within 30 min of incubation at pH 9, 200 µg substrate concentration, and 100 °C reaction temperature. The heart showed a high absorption of 32.39 ± 0.88% of the injected dose/g organ (ID/g), confirming the suitability of [99mTc]-technetium tricarbonyl PA as a viable complex for heart imaging.

Preparation, characterization, and bioevaluation of 99mTc-famotidine as a selective radiotracer for peptic ulcer disorder detection in mice

This work focuses on tracking peptic ulcer localized in mice. The formation of a [99mTc]dithiocarbamate of famotidine complex at optimum conditions of reaction temperature (37 °C), reaction time (30 min), pH of the reaction mixture (5), amount of substrate (100 µg), amount of reducing agent (tin (II) content, 50 µg), was achieved using radioactive Tc-99m (250–400 MBq), with labelling yield of 98% and high radiochemical purity. The in-vitro stability of [99mTc]dithiocarbamate of famotidine complex was shown to be high in rat serum for up to 8 h. Normal and ulcerated mice were used in biodistribution studies. Famotidine works by blocking histamine-2-receptor antagonists (H2RAs). The high absorption of [99mTc]dithiocarbamate of famotidine complex in stomach in amount of 27.15% injected dose/g organ (ID/g) observed in ulcerated mice for up to 24 h demonstrated its usefulness as a novel radiotracer for stomach imaging.

Radioiodinated esomeprazole as a model for peptic ulcer localization

This work focuses on tracking stomach ulcer localized in mice. High labeling yield and radiochemical purity were achieved for the formation of a [125I]esomeprazole radiotracer at optimum conditions of oxidizing agent content (chloramines-T (Ch-T), 100 μg), substrate amount (Esom, 100 μg), pH of reaction mixture (6), reaction time (30 min) and temperature (37 °C), using radioactive iodine-125 (200–450 MBq). The radiolabeled compound, [125I]esom, was stable in serum and saline solution during 24 h. Esom is acting as a histamine-2-receptor antagonist (H2RA). Biodistribution studies were carried in normal and ulcerated mice. High uptake of 78.12 ± 0.80% injected dose/g organ (ID/g) observed in ulcerated mice confirmed the suitability of [125I]esomeprazole as a novel radiotracer for stomach imaging.

Radioiodination and biological evaluation of Cimetidine as a new highly selective radiotracer for peptic ulcer disorder detection

One of the most famous techniques for stomach ulcer imaging is the nuclear imaging technique. We aim to focus on the synthesis of 125I-cimetidine (125I-cim) as an agent for peptic ulcer imaging. Cimetidine was labeled with Iodine-125 using a different oxidizing agent (Ch-T, NBS). All factors affecting the labeling yield were optimized. The radiochemical yield of 125I-cim was 98 ± 0.22% at optimum conditions. In vitro stability, in vivo biodistribution of 125I-cimetidine was studied in three groups: control group, pretreated group, and ulcer bearing group. In vivo biodistribution studies of 125I-cim revealed high uptake in the stomach ulcer, reaching about 75.4 ± 1.2% ID/g at 15 min post-injection, than pretreated groups compared to the control. The results showed the suitability of using 125I-cimetidine for stomach ulcer imaging.